Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

BACKGROUND: Folate binding protein(FBP) is an immunogenic protein over-expressed in endometrial(EC) and ovarian cancer(OC). We are conducting a phase I/IIa trial of E39 (GALE 301)+GM-CSF, an HLA-A2-restricted, FBP-derived peptide vaccine to prevent recurrences in disease-free EC and OC patients. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Doreen O., Byrd, Kevin, Vreeland, Timothy J., Hale, Diane F., Herbert, Garth S., Greene, Julia M., Schneble, Erika J., Berry, John S., Trappey, Alfred F., Travis Clifton, Guy, Hardin, Mark O., Martin, Jonathan, Elkas, John C., Conrads, Thomas P., Darcy, Kathleen M., Hamilton, Chad A., Maxwell, George L., Peoples, George E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362533/
https://www.ncbi.nlm.nih.gov/pubmed/27852036
http://dx.doi.org/10.18632/oncotarget.13305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362533/
https://www.ncbi.nlm.nih.gov/pubmed/27852036
http://dx.doi.org/10.18632/oncotarget.13305

Ejemplares similares